89
Views
1
CrossRef citations to date
0
Altmetric
Technical Notes

Analytical evaluation of direct bicarbonate measurement with the new gem premier chemstat in hemodialysis patients

, , , , , , , , & ORCID Icon show all
Pages 418-421 | Received 04 Mar 2021, Accepted 08 May 2021, Published online: 31 May 2021
 

Abstract

GEM Premier ChemSTAT is a whole-blood analyzer designed for providing a rapid basic metabolic panel, inclusive of creatinine and blood urea nitrogen, with the unique characteristic of providing measured bicarbonate (HCO3) levels. The aim of this work was to evaluate the clinical performance of HCO3 assessment with this analyser in a real-life hemodialysis setting. Imprecision was calculated at different HCO3 levels, along with assay comparison with Gem Premier 4000 analysers. GEM Premier ChemSTAT displayed an imprecision and a bias (in comparison to GEM Premier 4000) for HCO3 of 0.4% and 37.3% at 20.8 mmol/L, 1.2% and 25.6% at 16.4 mmol/L, and 2.1% and 11.6% at 11.5 mmol/L, respectively, using three levels of HCO3 quality control sample ChemSTAT System Evaluator. At direct comparison with the GEM Premier 4000 in the hemodialysis setting, Bland–Altman analysis of HCO3 levels evidenced a bias (µ) of −4.9 (95% CI, −5.2 to −4.7) mmol/L. Such difference was attenuated by recalculating the GEM ChemSTAT expected HCO3 values from pH and pCO2 using the Henderson Hasselbach equation, µ=–0.07 (95%CI, −0.19 to 0.05) mmol/L (p = .24). In conclusion, our results show a remarkable difference between the HCO3 values reported by GEM ChemSTAT or GEM 4000. New reference values for GEM ChemSTAT HCO3 shall hence be defined according to our findings. We suggest that further investigation and a re-evaluation of the reference range should be made before extending the clinical use of this device.

Acknowledgments

We would like to thank all the staff, nurses and patients of the IFCA Nephrology and Dialysis Unit, the laboratory staff and outpatients service nurses and patients.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.